Segment Information - Schedule of Total Revenues of Top Selling Products (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended		3 Months Ended										12 Months Ended		9 Months Ended
	Dec. 31, 2013 drug		Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012		Dec. 31, 2014		Sep. 28, 2012
Revenue, Major Customer [Line Items]
Number of other insignificant generic drugs	85
Successor [Member]
Revenue, Major Customer [Line Items]
Total revenues	1,097,467		$ 388,015	$ 336,117	$ 295,405	$ 289,084	$ 306,281	$ 267,321	$ 233,669	$ 290,196	$ 246,139		$ 1,308,621
Successor [Member] | Par Pharmaceutical [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	1,028,418										227,312		1,241,131
Successor [Member] | Par Pharmaceutical [Member] | Budesonide (Entocort EC) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	198,834										36,710		142,853
Successor [Member] | Par Pharmaceutical [Member] | Bupropion Er Wellbutrin [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	45,403										11,255		84,467
Successor [Member] | Par Pharmaceutical [Member] | Propafenone (Rythmol SR) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	70,508										19,623		75,966
Successor [Member] | Par Pharmaceutical [Member] | Amlodipine/Valsartan (Exforge) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	0										0		60,784
Successor [Member] | Par Pharmaceutical [Member] | Divalproex (Depakote) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	46,635										2,436		59,052
Successor [Member] | Par Pharmaceutical [Member] | Metoprolol Succinate Er Toprol Xl [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	56,670										31,287		46,251
Successor [Member] | Par Pharmaceutical [Member] | Clonidine ER (Kapvay) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	13,008										0		45,134
Successor [Member] | Par Pharmaceutical [Member] | Lamotrigine (Lamictal XR) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	54,577										0		40,673
Successor [Member] | Par Pharmaceutical [Member] | Aplisol [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	0										0		35,228
Successor [Member] | Par Pharmaceutical [Member] | Modafinil (Provigil) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	27,688										16,956		2,123
Successor [Member] | Par Pharmaceutical [Member] | Chlorpheniramine/Hydrocodone (Tussionex) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	33,518										17,403		26,899
Successor [Member] | Par Pharmaceutical [Member] | Other [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	450,148	[1]									83,491	[1]	594,751	[1]
Successor [Member] | Par Pharmaceutical [Member] | Other product related revenues [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	31,429	[2]									8,151	[2]	26,950	[2]
Successor [Member] | Par Specialty [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	69,049										18,827		67,490
Successor [Member] | Par Specialty [Member] | Other product related revenues [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	2,675	[2]									779	[2]	3,505	[2]
Successor [Member] | Par Specialty [Member] | Nascobal Nasal Spray [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	26,864										7,138		32,332
Successor [Member] | Par Specialty [Member] | Megace ES [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues	39,510										10,910		31,653
Predecessor [Member]
Revenue, Major Customer [Line Items]
Total revenues															803,868
Predecessor [Member] | Par Pharmaceutical [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															743,360
Predecessor [Member] | Par Pharmaceutical [Member] | Budesonide (Entocort EC) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															103,762
Predecessor [Member] | Par Pharmaceutical [Member] | Bupropion Er Wellbutrin [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															34,952
Predecessor [Member] | Par Pharmaceutical [Member] | Propafenone (Rythmol SR) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															53,825
Predecessor [Member] | Par Pharmaceutical [Member] | Amlodipine/Valsartan (Exforge) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															0
Predecessor [Member] | Par Pharmaceutical [Member] | Divalproex (Depakote) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															9,099
Predecessor [Member] | Par Pharmaceutical [Member] | Metoprolol Succinate Er Toprol Xl [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															154,216
Predecessor [Member] | Par Pharmaceutical [Member] | Clonidine ER (Kapvay) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															0
Predecessor [Member] | Par Pharmaceutical [Member] | Lamotrigine (Lamictal XR) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															0
Predecessor [Member] | Par Pharmaceutical [Member] | Aplisol [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															0
Predecessor [Member] | Par Pharmaceutical [Member] | Modafinil (Provigil) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															88,831
Predecessor [Member] | Par Pharmaceutical [Member] | Chlorpheniramine/Hydrocodone (Tussionex) [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															30,706
Predecessor [Member] | Par Pharmaceutical [Member] | Other [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															249,383	[1]
Predecessor [Member] | Par Pharmaceutical [Member] | Other product related revenues [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															18,586	[2]
Predecessor [Member] | Par Specialty [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															60,508
Predecessor [Member] | Par Specialty [Member] | Other product related revenues [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															4,615	[2]
Predecessor [Member] | Par Specialty [Member] | Nascobal Nasal Spray [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															17,571
Predecessor [Member] | Par Specialty [Member] | Megace ES [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues															$ 38,322

[1] The further detailing of revenues of the other approximately 85 generic drugs was not considered significant to the overall disclosure due to the lower volume of revenues associated with each of these generic products. No single product in the other category was significant to total generic revenues for the years ended December 31, 2014 (Successor) and December 31, 2013 (Successor), the period from September 29, 2012 to December 31, 2012 (Successor) or for the period from January 1, 2012 to September 28, 2012 (Predecessor).

[2] Other product related revenues represents licensing and royalty related revenues from profit sharing agreements.